T Cell News and Research

Latest T Cell News and Research

Vampire-like bacteria has potential to serve as living antibiotic

A vampire-like bacteria that leeches onto specific other bacteria - including certain human pathogens - has the potential to serve as a living antibiotic for a range of infectious diseases, a new study indicates.

1 Nov 2011

Light-cell interaction and Born approximation rule can help detect misshapen red blood cells

Misshapen red blood cells are a sign of serious illnesses, such as malaria and sickle cell anemia. Until recently, the only way to assess whether a person's RBCs were the correct shape was to look at them individually under a microscope - a time-consuming process for pathologists.

1 Nov 2011

Tregs expansion can help prevent graft-versus-host disease

Graft-versus-host disease (GVHD) is a serious risk in many kinds of cell transplants, including for stem cell transplants carried out when stem cells are partially depleted of conventional T cells, which play an important role in the immune system. Now, researchers at Moffitt Cancer Center have tested a process by which T regulatory cells (Tregs) can be "expanded" to help prevent GVHD.

1 Nov 2011

ER-positive breast cancer patients with high levels of heat shock factor 1 experience poor outcomes

Whitehead Institute scientists report that patients whose estrogen receptor (ER)-positive breast cancers have high levels of the ancient cellular survival factor heat shock factor 1 (HSF1) experience poor outcomes—including increased mortality.

1 Nov 2011

Cigarette smokers at risk of compromised digestive function

Cigarette smoking appears to impair pancreatic duct cell function--even for those who quit--putting all smokers at risk of compromised digestive function regardless of age, gender and alcohol intake, according to the results of a study unveiled today at the American College of Gastroenterology's (ACG) 76th Annual Scientific meeting in Washington, DC.

31 Oct 2011

Initiation of two IPI-145 Phase 1 clinical trials triggers $4M milestone payment to Intellikine

Intellikine, Inc., a company focused on the discovery and development of innovative, small molecule drugs targeting the PI3K/mTOR pathway, announced today that it has earned $4 million in milestone payments upon the initiation of two Phase 1 clinical trials of IPI-145.

31 Oct 2011

'Good bugs' promising against ulcerative colitis, psoriasis, chronic fatigue syndrome

In four different studies presented at the American College of Gastroenterology's (ACG) 76th Annual Scientific meeting in Washington, DC, researchers explored the effectiveness of probiotics for antibiotic-associated diarrhea; as an anti-inflammatory agent for patients with ulcerative colitis, psoriasis and chronic fatigue syndrome; and for people with abdominal discomfort and bloating who have not been diagnosed with a functional bowel disorder, such as irritable bowel syndrome (IBS).

31 Oct 2011

Haemonetics second quarter net revenues increase 8% to $179.4 million

Haemonetics Corporation today reported second quarter 2012 GAAP net revenues of $179.4 million, up 8%, net income of $13.9 million, down 35%, and earnings per share of $0.54, down 36%. Excluding transformation costs and contingent consideration income, adjusted second quarter net income was $18.7 million, down 7%, and adjusted earnings per share was $0.72, down 9%. Excluding currency impacts, net revenue was up 6% in the quarter.

31 Oct 2011

Infinity commences two IPI-145 Phase 1 clinical trials for hematologic malignancies

Infinity Pharmaceuticals, Inc. today announced that it has initiated two Phase 1 clinical trials of IPI-145, a potent, orally available inhibitor of phosphoinositide-3-kinase (PI3K) delta and gamma. These two enzymes are implicated in hematologic cancers as well as a broad range of inflammatory conditions, which are the areas of focus within Infinity's PI3K clinical development program.

31 Oct 2011

Positive initial results from CytRx's INNO-206 Phase 1b/2 clinical trial for advanced solid tumors

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced favorable response and safety indications from a group of patients with advanced solid tumors (principally soft tissue sarcomas) in the Company's ongoing Phase 1b/2 clinical trial with INNO-206, its tumor-targeting conjugate of the commonly used chemotherapeutic agent doxorubicin.

31 Oct 2011

AgonOx, MedImmune partner to advance OX40 agonist programs for cancer treatment

AgonOx today announced that it has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.

31 Oct 2011

Gen-Probe receives FDA approval for APTIMA HPV assay

Gen-Probe Incorporated announced today that the US Food and Drug Administration (FDA) has approved its APTIMA HPV assay, an amplified nucleic acid test that detects high-risk strains of human papillomavirus (HPV) that are associated with cervical cancer and precancerous lesions.

31 Oct 2011

Astex to present data on direct acting antiviral agents against HCV at 62nd AASLD meeting

Astex Pharmaceuticals, Inc., a pharmaceutical company dedicated to the discovery, development and commercialization of novel therapeutics, announced that it will present data on its novel, first-in-class direct acting antiviral agents (DAA) against Hepatitis C Virus (HCV) at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco, November 4-8, 2011.

31 Oct 2011

Fierce Vaccines highlights Inovio's VGX-3100 as one of 10 Promising Therapeutic Vaccines

Inovio Pharmaceuticals, Inc., which is advancing synthetic vaccines to fight cancers and infectious diseases, announced today that VGX-3100, its investigational SynCon vaccine for treating cervical dysplasia and cancer caused by human papillomavirus, was highlighted by Fierce Vaccines as one of 10 Promising Therapeutic Vaccines.

31 Oct 2011

Scientists identify key mechanism of tumor metastasis

Scientists at Dalhousie University in Nova Scotia have identified a key mechanism of metastasis that could lead to blocking tumor growth if their findings are confirmed.

31 Oct 2011

Researchers shed light on inner workings of endocycle

An international team of researchers led by investigators in the U.S. and Germany has shed light on the inner workings of the endocycle, a common cell cycle that fuels growth in plants, animals and some human tissues and is responsible for generating up to half of the Earth's biomass.

31 Oct 2011

New top-down method can quickly separate, identify thousands of protein molecules

A team led by Northwestern University chemical biologist Neil Kelleher has developed a new "top-down" method that can separate and identify thousands of protein molecules quickly. Many have been skeptical that such an approach, where each protein is analyzed intact instead of in smaller parts, could be done on such a large scale.

31 Oct 2011

Researchers identify FMRP protein as key player in RNA editing

The most common form of heritable cognitive impairment is Fragile X Syndrome, caused by mutation or malfunction of the FMR1 gene. Loss of FMR1 function is also the most common genetic cause of autism. Understanding how this gene works is vital to finding new treatments to help Fragile X patients and others.

31 Oct 2011

First report on how patterns of 5-hmC's distribution change in mouse brain during development

In 2009, the DNA alphabet expanded. Scientists discovered that an extra letter or "sixth nucleotide" was surprisingly abundant in DNA from stem cells and brain cells.

31 Oct 2011

Ovarian cancer patients with many folate receptors benefit from new therapy

A new strategy that takes advantage of ovarian cancer's reliance on folate appears to give relapse patients extra months of life with few side effects, researchers say.

29 Oct 2011

T Cell News and Research

Latest T Cell News and Research

Vampire-like bacteria has potential to serve as living antibiotic

Light-cell interaction and Born approximation rule can help detect misshapen red blood cells

Tregs expansion can help prevent graft-versus-host disease

ER-positive breast cancer patients with high levels of heat shock factor 1 experience poor outcomes

Cigarette smokers at risk of compromised digestive function

Initiation of two IPI-145 Phase 1 clinical trials triggers $4M milestone payment to Intellikine

'Good bugs' promising against ulcerative colitis, psoriasis, chronic fatigue syndrome

Haemonetics second quarter net revenues increase 8% to $179.4 million

Infinity commences two IPI-145 Phase 1 clinical trials for hematologic malignancies

Positive initial results from CytRx's INNO-206 Phase 1b/2 clinical trial for advanced solid tumors

AgonOx, MedImmune partner to advance OX40 agonist programs for cancer treatment

Gen-Probe receives FDA approval for APTIMA HPV assay

Astex to present data on direct acting antiviral agents against HCV at 62nd AASLD meeting

Fierce Vaccines highlights Inovio's VGX-3100 as one of 10 Promising Therapeutic Vaccines

Scientists identify key mechanism of tumor metastasis

Researchers shed light on inner workings of endocycle

New top-down method can quickly separate, identify thousands of protein molecules

Researchers identify FMRP protein as key player in RNA editing

First report on how patterns of 5-hmC's distribution change in mouse brain during development

Ovarian cancer patients with many folate receptors benefit from new therapy

Immunology eBook

How Pulp Fixin Is Turning Paper into High-Performance Sustainable Labware

A new method to measure intracellular water in biological systems

Obesity, GLP-1s, and metabolic care

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

How Pulp Fixin Is Turning Paper into High-Performance Sustainable Labware

A new method to measure intracellular water in biological systems

Obesity, GLP-1s, and metabolic care

Newsletters you may be interested in